[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-567979-105":53,"doc-detail-567979-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","vaping-evidence-risks-and-clinical-implications-for-health-professionals-march-18-2026","Vaping: Evidence, Risks, and Clinical Implications for Health Professionals - March 18, 2026","","Training materials and an explainer outline vaping for health professionals, spanning device components and mechanisms, epidemiology, and emerging trends. Key health risks are reviewed, including EVALI, and vaping is evaluated within risk-reduction contexts. The session summarizes supporting evidence and clinical trials, then emphasizes practical clinical and counseling strategies through interactive case scenarios. Disclosures note no conflicts and non-tobacco-industry funding, with grant-supported development and stated views not necessarily reflecting US HHS positions.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/vaping-evidence-risks-and-clinical-implications-for-health-professionals-march-18-2026/567979/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/vaping-evidence-risks-and-clinical-implications-for-health-professionals-march-18-2026/567979.png","ImageObject",442,249,{"name":88,"@type":89},"Muffet","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-19","2026-10-13",true,{"@type":98,"interactionType":99,"userInteractionCount":73},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What are the key learning objectives for this vaping training?","Question",{"text":108,"@type":109},"Participants are guided to describe vaping device components and mechanisms, summarize vaping epidemiology and trends, identify major health risks including EVALI, and evaluate vaping in risk-reduction contexts. The program also reviews evidence and clinical trials and applies clinical and counseling strategies.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"What disclosures are provided in the materials?",{"text":113,"@type":109},"The materials state there are no conflicts to declare and no funding or relationship with tobacco industry. Development was supported by a named grant, and the document clarifies that views and opinions do not necessarily reflect the US Department of Health and Human Services.",{"name":115,"@type":106,"acceptedAnswer":116},"How do the case scenarios frame vaping counseling for patients?",{"text":117,"@type":109},"The cases include a 54-year-old male with HIV who asks whether a vape is safer, another 54-year-old HIV patient who does not want to quit smoking despite being able to, and a 19-year-old college student whose friends encourage vaping for weight-related reasons. Each scenario prompts participants to decide what to tell the patient.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},567979,1792415055,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":73,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":30},962090768927,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Bridging the gap between science and service…  \nATTC Explainer Video  \nDisclosures  \n• The development of these training materials was supported by grant 7H79TI088149-01 (PI: R. Martin) from the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, United States Department of Health and Human Services . The views and opinions contained within this document do not necessarily reflect those of the US Department of Health and Human Services and should not be construed as such.  \nVaping: Evidence, Risks, and Clinical Implications for Health Professionals  \nPatricia A. Cioe, PhD  \nAssociate Dean of Research & Scholarship Professor  \nUniversity of Rhode Island College of Nursing March 18, 2026  \nDisclosures  \n􀂄 No conflicts to declare.  \n􀂄 No funding or relationship with tobacco industry.  \nLearning Objectives  \n􀂄 Describe the components and mechanisms of vaping devices  \n􀂄 Summarize vaping epidemiology and trends  \n􀂄 Identify key health risks , including review of EVALI  \n􀂄 Evaluate vaping in risk reduction context  \n􀂄 Review the evidence and clinical trials  \n􀂄 Apply clinical and counseling strategies  \nCase \\#1  \n􀂄 A 54-year old male with HIV presents to your office  \n􀂄 They say, “Doc, I’ve tried everything and I just can’t quit. I want to quit smoking but I don’t know if I can. What do you think about a vape? Is it safer for me?”  \n􀂄 Chart review: Stable on ART; Tcell count = 740, HIV VL undetectable; 1 ppd x 30+ years; mild hypertension, on a diuretic daily  \n􀂄 What do you tell him?  \nCase \\#2  \n􀂄 A 54-year old male with HIV presents to your office.  \n􀂄 They say, “Doc, I’ve given up everything since my diagnosis with HIV. I enjoy smoking and I don’t want to quit. I know I could if I wanted to, but I just don’t wanna quit.”  \n􀂄 Chart review: Stable on ART; Tcell count = 670, HIV VL undetectable; 1 ppd x 40 years; mild hypertension, on a diuretic daily  \n􀂄 What do you tell him?  \nCase \\#3  \n􀂄 A 19 y/o female college student presents for her annual GYN exam. She has been taking OCPs for about 1-2 years.  \n􀂄 She says she has never smoked but some of her friends are vaping, especially during weekend parties, and they are encouraging her to try it.  \n􀂄 “They say it suppresses their appetite so they don’t eat as much and helps them maintain their weight”.  \n􀂄 “I’m thinking about trying it.”  \n􀂄 What do you tell her?  \nCigarette smoking among adults in the U.S.  \n􀂄 Cigarette smoking remains the leading cause of preventable disease and death in the U.S.  \n􀂅 ~480,000 deaths per year  \n􀂄 12.5% of U.S. adults (≥18 years) use cigarettes (CDC, 2020)  \n􀂅 30.8 million people who smoke in the U.S.  \n􀂄 1 in 3 people who smoke will die from smokingrelated disease  \n􀂄 Only about 8% of adult smokers quit successfully annually","cbCaipceIDKIzgY6","https://ap.wps.com/l/cbCaipceIDKIzgY6","pdf",4131710,47,"English","# Learning Objectives\n## Disclosures\n## Case #1\n## Case #2\n## Case #3\n## Cigarette Smoking Among Adults in the U.S.","[{\"question\":\"What are the key learning objectives for this vaping training?\",\"answer\":\"Participants are guided to describe vaping device components and mechanisms, summarize vaping epidemiology and trends, identify major health risks including EVALI, and evaluate vaping in risk-reduction contexts. The program also reviews evidence and clinical trials and applies clinical and counseling strategies.\"},{\"question\":\"What disclosures are provided in the materials?\",\"answer\":\"The materials state there are no conflicts to declare and no funding or relationship with tobacco industry. Development was supported by a named grant, and the document clarifies that views and opinions do not necessarily reflect the US Department of Health and Human Services.\"},{\"question\":\"How do the case scenarios frame vaping counseling for patients?\",\"answer\":\"The cases include a 54-year-old male with HIV who asks whether a vape is safer, another 54-year-old HIV patient who does not want to quit smoking despite being able to, and a 19-year-old college student whose friends encourage vaping for weight-related reasons. Each scenario prompts participants to decide what to tell the patient.\"}]","Vaping: Evidence, Risks, and Clinical Implications for Health Professionals - March 18, 2026 | PDF",1791868824]